Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014 Apr;13(4):489-505.
doi: 10.1586/14760584.2014.894467.

Identifying vaccine targets for anti-leishmanial vaccine development

Shyam Sundar, Bhawana Singh
Review

Identifying vaccine targets for anti-leishmanial vaccine development

Shyam Sundar et al. Expert Rev Vaccines. 2014 Apr.

Abstract

Leishmaniasis is a neglected tropical disease spread by an arthropod vector. It remains a significant health problem with an incidence of 0.2–0.4 million visceral leishmaniasis and 0.7–1.2 million cutaneous leishmaniasis cases each year. There are limitations associated with the current therapeutic regimens for leishmaniasis and the fact that after recovery from infection the host becomes immune to subsequent infection therefore, these factors force the feasibility of a vaccine for leishmaniasis. Publication of the genome sequence of Leishmania has paved a new way to understand the pathogenesis and host immunological status therefore providing a deep insight in the field of vaccine research. This review is an effort to study the antigenic targets in Leishmania to develop an anti-leishmanial vaccine.

PubMed Disclaimer

References

    1. Berman J. Visceral leishmaniasis in the New World & Africa. Indian J Med Res. 2006;123:289–294. - PubMed
    1. Alvar J, Velez ID, Bern C, Herrero M, Desjeux P, Cano J, Jannin J, den Boer M. Leishmaniasis worldwide and global estimates of its incidence. PLoS One. 2012;7:e35671. - PMC - PubMed
    1. Handman E. Cell biology of Leishmania. Adv Parasitol. 1999;44:1–39. - PubMed
    1. Kedzierski L, Zhu Y, Handman E. Leishmania vaccines: progress and problems. Parasitology. 2006;133(Suppl):S87–S112. - PubMed
    1. Okwor I, Liu D, Uzonna J. Qualitative differences in the early immune response to live and killed Leishmania major: Implications for vaccination strategies against Leishmaniasis. Vaccine. 2009;27:2554–2562. - PubMed

Publication types

MeSH terms